ISPOR 17th Annual International Meeting - Released Presentations
 
RELEASED PRESENTATIONS


PLENARY SESSIONS
 
FIRST PLENARY SESSION:
COMPARING THE EFFECTIVENESS OF NEW DRUGS: SHOULD THE FDA BE ASKING 'DOES IT WORK' OR 'DOES IT WORK BETTER'?
COMPARING THE EFFECTIVENESS OF NEW DRUGS: SHOULD THE FDA BE ASKING ‘DOES IT WORK’ OR ‘DOES IT WORK BETTER’?
Sean R. Tunis, MD, MSc, President & CEO, Center for Medical Technology Policy, Baltimore, MD, USA
 
FDA DRUG APPROVAL PROCESS
Vicki L. Seyfert-Margolis, PhD, Senior Advisor, Science Innovation and Policy, Office of the Chief Scientist, Office of the Commissioner, U.S. Food and Drug Administration, Silver Spring, MD, USA
 

SECOND PLENARY SESSION:
HEALTH REFORM IN THE US: BETTER HEALTH, BETTER CARE, LOWER COST
The Health Care System In The United States: The Basics And Essentials For Reform
Susan Dentzer, MA,
Editor-in-Chief, Health Affairs, Bethesda, MD, USA
 
Inside National Health Reform: The Impact of the Affordable Care Act
John E. McDonough, DrPH, MPA, Professor of the Practice of Public Health, Director of the Center for Public Health Leadership, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
 
Health Reform in MARYLAND
Joshua M. Sharfstein, MD, Secretary, Maryland Department of Health and Mental Hygiene, Baltimore, MD, USA
 

THIRD PLENARY SESSION:
PERFORMANCE-BASED RISK-SHARING ARRANGEMENTS: GOOD PRACTICES FOR DESIGN, IMPLEMENTATION AND EVALUATION
Performance-Based Risk-Sharing Arrangements: Good Practices For Design, Implementation And Evaluation
Lou Garrison, PhD, Co-Chair, ISPOR Performance-Based Risk-Sharing Arrangements Good Practices Task Force and Professor, Pharmaceutical Outcomes Research and Policy Program, University of Washington School of Pharmacy, Seattle, WA, USA
 
Performance-Based Risk-Sharing Arrangements: Good Practices For Design, Implementation And Evaluation
Adrian Towse, MA, MPhil, Co-Chair, ISPOR Performance-Based Risk-Sharing Arrangements Good Practices Task Force and Director, Office of Health Economics, London, UK
 
Performance-Based Risk-Sharing Arrangements: Good Practices For Design, Implementation And Evaluation
Lou Garrison, PhD, Co-Chair, ISPOR Performance-Based Risk-Sharing Arrangements Good Practices Task Force and Professor, Pharmaceutical Outcomes Research and Policy Program, University of Washington School of Pharmacy, Seattle, WA, USA
 
Performance-Based Risk-Sharing Arrangements: Good Practices For Design, Implementation And Evaluation
Jens Grueger PhD
, Vice President & Head, Global Health Economics & Pricing, F. Hoffmann-LaRoche Ltd, Basel, Switzerland
 
Performance-Based Risk-Sharing Arrangements: Good Practices For Design, Implementation And Evaluation
Penny Mohr, MA, Vice President of Program Development, Center for Medical Technology Policy, Baltimore, MD, USA
 
Performance-Based Risk-Sharing Arrangements: Good Practices For Design, Implementation And Evaluation
Andrew H. Briggs, DPhil, MSc, William R. Lindsay Chair of Health Economics, Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK
 

PODIUM AND POSTER PRESENTATIONS
 

For contributed research podium and poster abstracts and released slide or poster presentations for the ISPOR 17th Annual International Meeting, see: ISPOR Outcomes Research Digest an electronic database of over 18,700 research papers presented at ISPOR Annual International Meetings, ISPOR Annual European Congresses, and biennial ISPOR Asia-Pacific & Latin America Conferences from 1998 to date.

  • ISPOR Outcomes Research Digest:  http://www.ispor.org/research_study_digest/research_index.asp
  • Under Meeting select 17th Annual International Meeting – Washington, DC, USA - 2012
  • Select Search for all research podium and poster abstracts and available slide or poster presentations from the meeting. Alternatively search by disease/disorder, topic or subtopic.

 WORKSHOP PRESENTATIONS

(Presentations to be added pending speaker approval)

 
W1: FUNDAMENTALS OF MODEL CALIBRATION: THEORY & PRACTICE

Fundamentals of Model Calibration: Theory & Practice
Douglas Taylor, MBA, Associate Director, Ironwood Pharmaceuticals Inc, Cambridge, MA USA; Ankur Pandya, PhD, MPH, Graduate Student, Harvard University, Boston, MA USA; David Thompson, PhD, Executive Vice President & Senior Scientist, OptumInsight, Boston, MA USA

 
W2: ELICITING PATIENT-CENTERED OUTCOMES: DETERMINING THE RELATIVE STRENGTHS, OPPORTUNITIES AND CHALLENGES OF 5 COMMON RESEARCH DESIGNS
Eliciting Patient-Centered Outcomes: Determining the Relative Strengths, Challenges and Opportunities of Six Common Research Designs
Bryan R. Luce, PhD, MBA, United BioSource Corporation, Bethesda, MD; Lori Frank, PhD, Patient Centered Outcomes Research Institute, Washington, DC; Karin S. Coyne, PhD, MPH, United BioSource Corporation, Bethesda, MD; Kathleen W. Wyrwich, PhD, United BioSource Corporation, Bethesda, MD

 

W6: DISTRIBUTED SEQUENTIAL COHORT ANALYSES FOR RAPID EVIDENCE GENERATION IN THE EARLY MARKETING PERIOD
Distributed sequential cohort analyses for rapid evidence generation in the early marketing period
Joshua Gagne, PharmD, ScD, Instructor in Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Sebastian Schneeweiss, MD, ScD, Associate Professor of Medicine and Epidemiology & Vice Chief, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Jeremy A. Rassen, ScD, Assistant Professor of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Jens Grueger, PhD, Vice President & Head, Global Health Economics & Pricing, F. Hoffmann-LaRoche Ltd, Basel, Switzerland

 

W8: INTRODUCTION TO USE OF INFORMATIVE VARIANCE PRIORS AND ADVANCED HETEROGENEITY MODELLING ISSUES IN RANDOM-EFFECTS MULTIPLE TREATMENT COMPARISON META-ANALYSIS

Variance Priors in Multiple Treatment Comparisons – Are Informative Priors the Better Solution?
Kristain Thorlund, PhD, Assistant Professor, McMaster University, Hamilton, ON, Canada

Why do we need better network meta-analyses?
Edward Mills, PhD, MSc,
Associate Professor, University of Ottawa, Ottawa, ON, Canada

An Example of the Use of Informative Priors: An Analysis of Within Trial Variation
Neil Hawkins, PhD, Director, Oxford Outcomes Ltd., Oxford, UK

 
W11: DEVELOPING GUIDANCE FROM HTA AND COVERAGE BODIES TO INFORM CLINICAL TRIAL DESIGN: THE GREEN PARK COLLABORATIVE

The Changing Requirements of Payers in Evaluating New Health Care Technologies
Marc L. Berger, MD, Executive Vice President & Senior Scientist, Life Sciences, OptumInsight, New York, NY, USA

 
W12: ADAPTING TO EVOLVING GLOBAL EVIDENCE REQUIREMENTS IN MEDICAL DEVICE DEVELOPMENT PROGRAMS
ADAPTING TO EVOLVING GLOBAL EVIDENCE REQUIREMENTS IN MEDICAL DEVICE DEVELOPMENT PROGRAMS
Thomas Goss, PharmD, Vice President, Boston Healthcare Associates, Inc., Boston, MA, USA; Liesl Cooper, PhD, Vice President, Global Healthcare Economics, Policy & Reimbursement, Covidien, Mansfield, MA, USA; Bernd Brueggenjuergen, MD, MPH, Managing Director, Boston Healthcare GmbH, Celle, Germany
 
W14: REAL WORLD EVIDENCE: FEASIBILITY AND ADVANTAGES OF LINKING PAYER AND PRACTITIONER DATA FOR RESEARCH
Real World Evidence: Feasibility and Advantages of Linking Payer and Practitioner Data for Research
Chakkarin Burudpakdee, PharmD, Director, Health Economics and Outcomes Research, IMS Health Consulting Group, Alexandria, VA, USA; Jerrold Hill, PhD, Engagement Manager, HEOR, IMS Health, Plymouth Meeting, PA, USA; Dennis Raisch, PhD, RPh, MS, Professor & Chair, PEPPOR Graduate Program, University of New Mexico College of Pharmacy, Albuquerque, NM, USA
 
W17: THE NUTS AND BOLTS OF PRESENTING EVIDENCE TO HEALTH AUTHORITIES
THE NUTS AND BOLTS OF PRESENTING EVIDENCE TO HEALTH AUTHORITIES
Shelby D. Reed, PhD, Associate Professor, Duke Clinical Research Institute, Durham, NC, USA; Scott Ramsey, PhD, MD, Member, Fred Hutchinson Cancer Research Center & Professor, School of Medicine, University of Washington, Seattle, WA, USA; Michael Iskedjian, MSc, President, PharmIdeas Research and Consulting and Professor, Université de Montréal, Montréal, QC, Canada; John O'Donnell, PhD, MA, Vice President, Global Health Economics and Outcomes Research, Bristol-Myers Squibb Company, Princeton, NJ, USA
 
W19: COMPARATIVE EFFECTIVENESS RESEARCH: METHODS AND APPLICATIONS

Patient-Reported Outcomes in Comparative Effectiveness Research
Donald L. Patrick, PhD, MSPH, Professor, Department of Health Services; Director, Seattle Quality of Life Group, University of Washington, Seattle, WA, USA

Gaining Efficiency, Flexibility and Applicability for CER Trials: The READAPT (REsearch in ADAptive methods for Pragmatic Trials) Study Design
Jack Ishak, PhD, MSc, BSc, Director & Research Scientist Biostatistics, United BioSource Corporation, Dorval, QC, Canada

Patient and Stakeholder Engagement in CER
C. Daniel Mullins, PhD, Professor, Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, MD, USA

 
W20: USING METHODS OF EXPERIMENTAL ECONOMICS TO INVESTIGATE INDIVIDUAL DETERMINANTS OF ADHERENCE AND IMPLICATIONS FOR MECHANISMS TO NUDGE PATIENTS' BEHAVIOR
Using Methods of Experimental Economics to Investigate Individual Determinants of Adherence and Implications for Mechanisms to Nudge Patients‘ Behavior
Behnud Mir Djawadi, Research Associate, Department of Management, University of Paderborn, Paderborn, Germany; René Fahr, Full Professor, Department of Management, University of Paderborn, Paderborn, Germany; Florian Turk, Global Head, Health Economics & Outcomes Research, Critical Care Business Franchise, Novartis Pharma AG, Basel, Switzerland
 
W22: EARLY ECONOMIC EVALUATION OF THE EFFECTIVENESS OF PHARMACEUTICAL DEVELOPMENT CANDIDATES IN SUBPOPULATIONS: A ROLE FOR CLINICAL TRIAL MODELING AND SIMULATION
EARLY ECONOMIC EVALUATION OF THE EFFECTIVENESS OF PHARMACEUTICAL DEVELOPMENT CANDIDATES IN SUBPOPULATIONS: A ROLE FOR CLINICAL TRIAL MODELING AND SIMULATION
Ananth Kadambi, PhD, Director, Modeling and Simulation Development & Research Scientist, Health Economics, United BioSource Corporation, Lexington, MA, USA; Robert Leipold, PhD, Research Scientist, Health Economics, United BioSource Corporation, Bethesda, MD, USA; Lyn Powell, PhD, Vice President, Strategic Relations and Senior Research Fellow, Entelos, Inc, San Mateo, CA, USA; Christy J. Chuang-Stein, PhD, Vice President, Statistical Research and Consulting Center, Pfizer, Inc., Kalamazoo, MI, USA
 
W23: ESTIMATING COST-EFFECTIVENESS RATIOS FROM CLINICAL TRIALS WITH MISSING DATA: A COMPARISON OF THE KAPLAN-MEIER SAMPLE AVERAGE STATISTIC AND THE JOINT MIXED-EFFECTS AND LOGGED TIME-TO-DROPOUT MODEL
ESTIMATING COST-EFFECTIVENESS RATIOS FROM CLINICAL TRIALS WITH MISSING DATA: A COMPARISON OF THE KAPLAN-MEIER SAMPLE AVERAGE STATISTIC AND THE JOINT MIXED-EFFECTS AND LOGGED TIME-TO-DROPOUT MODEL
Dennis D. Gagnon, MA, MABE, Senior Director, Strategic Consulting, Thomson Reuters, Santa Barbara, CA, USA; Silas Martin, MS, BA, Director, Metabolics, Health Economics & Outcomes Research, Janssen Scientific Affairs, LLC, Raritan, NJ, USA
 
W30: CHALLENGES AND RECOMMENDATIONS RELATED TO ASSURING QUALITY OUTCOMES DATA COLLECTED VIA ELECTRONIC PLATFORMS
Challenges and Recommendations Related to Assuring Quality Outcomes Data Collected via Electronic Platforms
Linda S Deal, MS, Head, Health Outcomes, eResearch Technology Inc, Philadelphia, PA, USA; Paul O'Donohoe, BSc, Manager of Health Outcomes, CRF Health, London, UK; Jean Paty, PhD, Chief Scientist and Regulatory Officer, PRO Consulting, Invivodata Ltd., Pittsburgh, PA, USA; Diane Wild, MSc, Vice President, ePRO and Translations, Oxford Outcomes Ltd., an ICON PLC Company, Oxford, Oxon, UK
 
W31: POWERFUL DATA, MEANINGFUL ANSWERS: INTRODUCTION TO THE HEALTH CARE COST AND UTILIZATION PROJECT
POWERFUL DATA, MEANINGFUL ANSWERS: INTRODUCTION TO THE HEALTH CARE COST AND UTILIZATION PROJECT
P. Hannah Davis, MS, Senior Program Analyst, Center for Delivery, Organization and Markets, Agency for Healthcare Research and Quality, Rockville, MD, USA; Jared Lane Maeda, PhD, MPH, Research Leader, Healthcare Business Section, Thomson Reuters, Washington, DC, USA
 
ISSUE PANEL PRESENTATIONS

(Presentations to be added pending speaker approval)

 

IP2: WILL CER STIMULATE OR DEPRESS INNOVATION IN HEALTH CARE?
Harnessing CER to stimulate health care innovation
Darius Lakdawalla, PhD, Associate Professor, Price School of Public Policy, University of Southern California, Los Angeles, CA, USA
 
IP3: THE COST-EFFECTIVENESS OF COST-EFFECTIVENESS ANALYSIS (CEA) IN COMPARATIVE EFFECTIVENESS RESEARCH (CER): WHEN IS CONDUCT OF CEA IN CONJUNCTION WITH CER REQUIRED?
The Cost Effectiveness of Cost Effectiveness Analysis in Comparative Effectiveness Research: When is Conduct of CEA in Conjunction With CER Required?
Patrick H. Conway, MD, MSCE, Chief Medical Officer & Director, Office of Clinical Standards & Quality, Centers for Medicare & Medicaid Services (CMS), Baltimore, MD, USA; Mark V. Pauly, PhD, Bendheim Professor of Health Care Systems, Insurance & Economics, The Wharton School, University of Pennsylvania, Philadelphia, PA, USA; Richard J. Willke, PhD, Senior Director & Group Lead, Global Health Economics & Outcomes Research, Pfizer, Inc., New York, NY, USA; Joe V. Selby, MD, MPH, Executive Director, Patient Centered Outcomes Research Institute (PCORI), Washington, DC, USA

 

IP4: HOW WILL FDA'S NEW DRAFT GUIDANCE ON UNSOLICITED REQUESTS FOR OFF-LABEL INFORMATION AFFECT AMCP DOSSIERS AND THE COMMUNICATION OF HEALTH ECONOMIC INFORMATION?

How will it affect AMCP Dossiers and the communication of health economic information?
Peter J. Neumann, ScD, Professor and Director, The Center for the Evaluation of Value and Risk in Health, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

An Overview of the Draft Guidance
Elaine Hu Cunningham, PharmD
, Senior Regulatory Review Officer, Office of Prescription Drug Promotion, U.S. Food and Drug Administration, Silver Spring, MD, USA

FDA Unsolicited Request and the AMCP Format
Sean D. Sullivan, PhD, RPh, MS, Professor of Pharmacy and Public Health, Director, Pharmaceutical Outcomes Research and Policy Program, Associate Dean for Research, School of Pharmacy, University of Washington, Seattle, WA, USA

 
IP5: SHOULD ORPHAN DRUGS BE SUBJECTED TO VALUE-BASED ASSESSMENTS?
Researcher Perspective
Amy K. O'Sullivan, PhD, Director, Health Economics & Outcomes Research, OptumInsight, Medford, MA, USA
 
IP6: ONCOLOGY COMPARATIVE EFFECTIVENESS RESEARCH: WHAT IS IT AND WHAT MAKES IT USEFUL?
Principles for the Conduct and Reporting of Comparative Effectiveness Research in Oncology
Scott Ramsey, PhD, MD, Member, Fred Hutchinson Cancer Research Center and Professor, Department of Medicine, University of Washington, Seattle, WA, USA; Sean D. Sullivan, PhD, RPh, MS, Professor of Pharmacy and Public Health, Director, Pharmaceutical Outcomes Research and Policy Program, Associate Dean for Research, School of Pharmacy, University of Washington, Seattle, WA, USA; Art Small, MD, Head, Oncology Outcomes Research, US Medical Affairs, Genentech, Inc., South San Francisco, CA, USA
 
IP7: DO DECISION MAKERS REALLY USE BUDGET IMPACT MODELS GENERATED BY PHARMACEUTICAL MANUFACTURERS?
Do Decision Makers Really Use Budget Impact Models Generated by Manufacturers?
Kathleen E. Hughes, MBA, Vice President, Health Economics and Outcomes Services, Avalere Health LLC, Washington, DC, USA
 
IP8: ACCELERATING THE DEVELOPMENT OF COMPARATIVE EFFECTIVENESS INFORMATION: DOES PHASE 3B REPRESENT AN OPPORTUNITY?

Accelerating the development of Comparative Effectiveness Information: Does Phase IIIb represent an opportunity?
Marc L. Berger, MD, Executive Vice President & Senior Scientist, Life Sciences, OptumInsight, New York, NY, USA

Accelerating the development of c-e information: Does phase 3b represent an opportunity?
Hans-Georg Eichler, MD, MSc, Senior Medical Officer, European Medicines Agency, London, UK

CER: Does Phase 3B Represent an Opportunity
Robert Temple, MD, Director of the Office of Medical Policy, U.S. Food and Drug Administration, Silver Spring, MD, USA

 
IP9: OUTSIDER PERSPECTIVES ON THE UNITED STATES COMPARATIVE EFFECTIVENESS RESEARCH MOVEMENT: REAL PROGRESS OR REAL DISAPPOINTMENT?

Outsider Perspectives on the US Comparative Effectiveness Research Movement: Real Progress or Real Disappointment?
David Thompson, PhD
, Senior Vice President, Life Sciences, OptumInsight, Medford, MA, USA

Outsider Perspectives on the UNITED STATES Comparative Effectiveness Research Movement: Real Progress or Real Disappointment?
Federico Augustovski, MD, MSc, Director, Health Economic Evaluation and Technology Assessment Department, Hospital Italiano de Buenos Aires, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina

Outsider Perspectives on The United States Comparative Effectiveness Research Movement: Real Progress or Real Disappointment?
Don Husereau, BScPharm, MSc, Adjunct Professor, Faculty of Medicine, University of Ottawa and Senior Scientist, University for Health Sciences, Medical Informatics and Technology, Tirol, Austria

 
IP10: STAKEHOLDER ENGAGEMENT IN PATIENT-CENTERED OUTCOMES RESEARCH (PCOR): CAN WE MAKE IT MEANINGFUL?
Stakeholder Engagement in Patient-Centered Outcomes Research (PCOR): Can We Make It Meaningful?
Patricia A. Deverka, MD, MS, Senior Research Director, Center for Medical Technology Policy, Baltimore, MD, USA; Jessie Gruman, PhD, President, Center for Advancing Health, Washington, DC, USA; Eleanor Perfetto, MS, PhD, Senior Director, Pfizer, Inc., Washington, DC, USA; Melissa McPheeters, MPH, PhD, Research Associate Professor & Co-Director, Vanderbilt Evidence-based Practice Center, Co-Director, Emphasis Program Area on Healthcare and Public Health Research and Management, Deputy Director, Women’s Health Research, Institute for Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN, USA
 
IP11: NEED FOR SPEED - IS IT POSSIBLE TO EFFICIENTLY GENERATE AND INTERPRET COMPARATIVE EFFECTIVENESS RESEARCH FOR NEWLY MARKETED DRUGS IN TIME TO MAKE INFORMED DECISIONS?
Need for Speed - Is it possible to efficiently generate and interpret comparative effectiveness research for newly marketed drugs in time to make informed decisions?
Kristijan H. Kahler, PhD, RPh, Executive Director, Outcomes Research Methods & Analytics, Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
 
IP12: CENTRALIZED VERSUS DECENTRALIZED HEALTH TECHNOLOGY ASSESSMENT: WHICH IS BETTER IN SUPPORTING VALUE-BASED PRICING AND MANAGED ENTRY OF PHARMACEUTICALS AND NEW TECHNOLOGIES? Centralized Versus Decentralized Health Technology Assessment: Which is Better in Supporting Value-Based Pricing and Managed Entry of Pharmaceuticals and New Technologies?
Don Husereau, BScPharm, MSc, Adjunct Professor, Faculty of Medicine, University of Ottawa and Senior Scientist, University for Health Sciences, Medical Informatics and Technology, Tirol, Austria
 
IP13: CUTTING THE FOG: HAVE WE REACHED CLARITY ON DIAGNOSTICS AND PERSONALIZED MEDICINE EVIDENCE EXPECTATIONS?
CUTTING THE FOG: HAVE WE REACHED CLARITY ON DIAGNOSTICS AND PERSONALIZED MEDICINE EVIDENCE EXPECTATIONS? The Manufacturers’ Perspective
Chandra Branham, JD, Vice President, Payment and Health Care Delivery Policy, The Advanced Medical Technology Association (AdvaMed), Washington, DC, USA
 
IP14: PATIENT-CENTERED BENEFIT-RISK ASSESSMENT: IS THERE A ROLE FOR PATIENT PREFERENCES IN QUANTITATIVE BENEFIT-RISK ASSESSMENT?
Patient centered benefit-risk assessment. Is there a role for patient preferences?
Maarten IJzerman, PhD, Professor, Dept. of Health Technology and Services Research, University of Twente, Enschede, The Netherlands; Dennis W Raisch, PhD, RPh, MS, Professor & Chair, PEPPOR Graduate Program, University of New Mexico College of Pharmacy, Albuquerque, NM, USA
 
IP15: WHAT IS THE VALUE OF CLASSICAL TEST THEORY, ITEM RESPONSE THEORY, AND RASCH MEASUREMENT THEORY IN THE DEVELOPMENT OF PATIENT-REPORTED OUTCOME INSTRUMENTS?
What is the Value of Classical Test Theory, Item Response Theory, and Rasch Measurement Theory in the Development of Patient-Reported Outcome Instruments?
Jennifer Petrillo, PhD, Associate Director, Global Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Stefan Cano, PhD, Chartered Psychologist & Director, SCALEREPORT, Stotfold, UK; Lori McLeod, PhD, Head, Psychometrics, Patient-Reported Outcomes, RTI Health Solutions, Research Triangle Park, NC, USA; Cheryl Coon, PhD, Director, Psychometrics, Patient-Reported Outcomes, RTI Health Solutions, Research Triangle Park, NC, USA
 
ISPOR FORUMS

ASSESSING NETWORK META ANALYSIS STUDIES: A PROPOSED MEASUREMENT TOOL FOR HEALTH CARE DECISION MAKERS
Presented by the CER-CI: Interpreting Indirect Treatment Comparison Studies for Health Care Decision Makers Task Force
Jeroen Jansen, PhD, Chair, CER-CI Interpreting Indirect Treatment Comparison Studies for Health Care Decision Makers Task Force and Vice President, Health Economics & Outcomes Research, MAPI Consultancy, Boston, MA, USA; Jessica Daw, PharmD, MBA, Director, Clinical Pharmacy UPMC Health Plan, Pittsburgh, PA, USA

MIXING MODES OF PATIENT-REPORTED OUTCOMES DATA COLLECTION IN CLINICAL TRIALS: RECOMMENDATIONS
Presented by the ISPOR PRO Mixed Modes Task Force
Sonya Eremenco, MA, Chair, ISPOR PRO Mixed Modes of Data Collection Task Force and ePRO Manager, United BioSource Corporation, Bethesda, MD, USA; Stephen Joel Coons, PhD, MS, MEd, Director, Patient-Reported Outcomes Consortium, Critical Path Institute, Tucson, AZ, USA; Jean Paty, PhD, Chief Scientist and Regulatory Officer, invivodata, inc., Pittsburgh, PA, USA

ASSESSING PROSPECTIVE OBSERVATIONAL STUDIES: A PROPOSED MEASUREMENT TOOL FOR HEALTH CARE DECISION MAKERS
Presented by the CER-CI: Interpreting Prospective Observational Studies for Health Care Decision Makers Task Force
Marc Berger, MD, Chair, CER-CI Interpreting Prospective Observational Studies for Health Care Decisions Task Force and Executive Vice President & Senior Scientist, OPTUMInsight, New York, NY, USA; C. Daniel Mullins, PhD, Professor, University of Maryland School of Pharmacy, Pharmaceutical Health Services Research, Baltimore, MD, USA; John Graham, PharmD, Group Director, Health Services, US Medical, Bristol-Myers Squibb, Princeton, NJ, USA; Scott Devine, MPH, PhD, Outcomes Research Scientist, US Outcomes Research, Merck & Co, Inc., St. Louis, MO, USA

ASSESSING MODELING STUDIES: A PROPOSED MEASUREMENT TOOL FOR HEALTH CARE DECISION MAKERS
Presented by the CER-CI: Interpreting Modeling Studies for Health Care Decision Makers Task Force
Cheryl Kaltz, RPh, MBA, Lead Clinical Pharmacist, The University of Michigan Prescription Drug Plan, University of Michigan, Ann Arbor, MI, USA; David Eddy, MD, PhD, Chair, CER-CI Interpreting Modeling Studies for Health Care Decisions Task Force and Founder & Medical Director, Archimedes Inc., San Francisco, CA, USA; J. Jaime Caro, MDCM, FRCPC, FACP, Adjunct Professor of Medicine, Adjunct Professor of Epidemiology and Biostatistics, McGill University and Senior Vice-President, Research, United BioSource Corporation, Lexington, MA, USA

ISPOR HEALTH ECONOMIC EVALUATION PUBLICATION GUIDELINES - CHEERS: GOOD REPORTING PRACTICES
Presented by the ISPOR Health Economic Evaluation Publication Guidelines – CHEERS Task Force
Don Husereau, BScPharm, MSc, Chair, ISPOR Health Economic Evaluation Publication Guidelines Task Force, Adjunct Professor, Faculty of Medicine, University of Ottawa and Senior Scientist, University for Health Sciences, Medical Informatics and Technology, Tirol, Austria; Chris Carswell, MSc, Editor, Pharmacoeconomics, Auckland, New Zealand; Michael Drummond, PhD, Co-Editor-in-Chief, Value in Health and Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK; Josephine Mauskopf, PhD, Former Editor-in-Chief, Value in Health and Vice President of Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA

PROS & CONS OF PRICING AND REIMBURSEMENT SYSTEMS IN SAUDI ARABIA, EGYPT, UNITED ARAB EMIRATES, QATAR AND JORDAN
Presented by the ISPOR Arabic Network
Ibrahim Alabbadi, PhD, MBA, President, ISPOR Jordan Regional Chapter, Associate Professor of Pharmacoeconomics & Pharmaceutical Marketing, Faculty of Pharmacy and Deputy General Manager, Administrative Affairs, Jordan University Hospital, University of Jordan, Amman, Jordan

PROS & CONS OF PRICING AND REIMBURSEMENT: Saudi Arabia health care system
Abdulaziz H. Al-Saggabi, MSc, PharmD,
President, ISPOR Saudi Arabia Regional Chapter and Director, Drug Policy & Economics Center, National Guard Health Affairs, Riyadh, Kingdom of Saudi Arabia

Drug Pricing & Reimbursement in Qatar
Daoud Al-Badriyeh, PhD, Assistant Professor of Pharmacoeconomics, College of Pharmacy, Qatar University, Doha, Qatar

PROS & CONS OF PRICING AND REIMBURSEMENT SYSTEMS IN EGYPT
Mahmoud Elmahdawy, PharmD, President, ISPOR Egypt Regional Chapter and Director, Hospital Pharmacy Administration, Central Administration for Pharmaceutical Affairs, Egyptian Ministry of Health, Cairo, Egypt

A Glimpse of Pricing and Reimbursement in the UAE
Ghaleb Ahmed Al Ahdab, PhD, President, ISPOR United Arab Emirates Regional Chapter, Pharmaceutical Advisor, Drug Registration Department, Ministry of Health and Assistant Professor of Pharmacy Practice, College of Pharmacy, Sharjah University and Ajman University of Science and Technology, Abu Dhabi, United Arab Emirates

ASSESSING RETROSPECTIVE OBSERVATIONAL STUDIES: A PROPOSED MEASUREMENT TOOL FOR HEALTH CARE DECISION MAKERS
Presented by the CER-CI: Interpreting Retrospective Observational Studies for Health Care Decision Makers Task Force
Marc Berger, MD, Chair, CER-CI Interpreting Prospective Observational Studies for Health Care Decisions Task Force and Executive Vice President & Senior Scientist, OPTUMInsight, New York, NY, USA; C. Daniel Mullins, PhD, Professor, University of Maryland School of Pharmacy, Pharmaceutical Health Services Research, Baltimore, MD, USA; John Graham, PharmD, Group Director, Health Services, US Medical, Bristol-Myers Squibb, Princeton, NJ, USA; Scott Devine, MPH, PhD, Outcomes Research Scientist, US Outcomes Research, Merck & Co, Inc., St. Louis, MO, USA

ASSESSING THE BODY OF EVIDENCE ACROSS MULTIPLE STUDIES: A PROPOSED MEASUREMENT TOOL FOR HEALTH CARE DECISION MAKERS
Presented by the CER-CI: Synthesizing a Body of Evidence Task Force
Helen Sherman, PharmD, Co-Chair, CER-CI Synthesizing a Body of Evidence Task Force and Chief Pharmacy Officer of Pharmacy Services, RegenceRx, Portland, OR, USA; Brian Sweet, MBA, Co-Chair, CER-CI Synthesizing a Body of Evidence Task Force and Executive Director Development, Managed Markets, AstraZeneca Pharmaceuticals, L.P., Wilmington, DE, USA

ISPOR GOOD RESEARCH PRACTICES FOR THE ASSESSMENT OF PATIENT-REPORTED OUTCOMES IN CHILDREN AND ADOLESCENTS
Presented by the Patient-Reported Outcomes Assessment in Children and Adolescents Task Force
Louis Matza, PhD, Chair, ISPOR Pediatric and Adolescent PRO Task Force andResearch Scientist, Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD, USA; John J. Alexander, MD, MPH, Medical Team Leader, Division of Anti-Infective and Ophthalmology Products, US Food and Drug Administration (FDA), Silver Spring, MD, USA; Donald L. Patrick, PhD, MSPH, Professor, Department of Health Services and Director, Seattle Quality of Life Group, University of Washington, Seattle, WA, USA; Anne W. Riley, PhD, MS, Professor, Department of Population, Family & Reproductive Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA

DESIGNING CONJOINT EXPERIMENTS: A GUIDE TO ALTERNATIVE STRATEGIES
Presented by the ISPOR Conjoint Analysis Experimental Design Task Force
John F. P. Bridges, PhD, Associate Professor, Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Emily Lancsar, PhD, Associate Professor, Centre for Health Economics, Faculty of Business and Economics, Monash University, Melbourne, Victoria, Australia; F. Reed Johnson, PhD, Chair, ISPOR Conjoint Analysis Experimental Design Task Force, Distinguished Fellow and Principal Economist, Health Preference Assessment Group, RTI Health Solutions, RTI International, Research Triangle Park, NC, USA; Axel Muehlbacher, PhD, Professor, Health Economics and Health Care Management, Hochschule Neubrandenburg, Neubrandenburg, Germany

ISPOR VISION 2020: A LOOK TO THE FUTURE
Presented by the ISPOR Vision 2020 Implementation Task Force

ISPOR VISION 2020: Research Initiatives
Ansgar Hebborn, PhD, ISPOR Vision 2020 Implementation Task Force Research Working Group Chair & Head - Global Payer & HTA Program Policy, F. Hoffmann-La Roche AG, Basel, Switzerland

ISPOR Vision 2020 Education Workgroup
Sean D. Sullivan, PhD, RPh, MS, ISPOR Vision 2020 Implementation Task Force Education Working Group Chair & Professor of Pharmacy and Public Health, Director, Pharmaceutical Outcomes Research and Policy Program, Associate Dean for Research, School of Pharmacy, University of Washington, Seattle, WA, USA

ISPOR Vision 2020 Communication Initiatives
Shelby D. Reed, PhD, ISPOR Vision 2020 Implementation Task Force Communications Working Group Chair & Associate Professor, Duke Clinical Research Institute, Durham, NC, USA

INTERNATIONAL PERSPECTIVES ON CHANGING EVIDENCE REQUIREMENTS FOR MEDICAL DEVICES AND DIAGNOSTICS: ADDRESSING THE MOVING TARGET PROBLEM FOR MEDICAL TECHNOLOGIES
Presented by the ISPOR HTA Special Interest Group
Annie Chicoye, PhD, Chair, ISPOR HTA of Medical Devices & Diagnostics Working Group and Executive Director for Development, Health Management Institute, ESSEC Business School Paris-Singapore, Cergy Pontoise Cedex, France; Susan Garfield, PhD, Vice President, Bridgehead International, Wayland, MA, USA; Eric Faulkner, MPH, Director, Global Market Access, Quintiles and Executive Director, Genomics, Biotech, Emerging Medical Technology Institute, National Association of Managed Care Physicians and Assistant Professor, Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC, USA; Sophie Cros, PharmD, MBA, Director, Regulatory Affairs, Reimbursement and Health Economics, EMA, Abbott Vascular International BVBA, Diegem, Belgium; Ataru Igarashi, PhD, Assistant Professor, Department of Drug Policy and Management Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan

PROBLEMS, PITFALLS, AND PRAGMATICS OF PHARMACOECONOMICS: LESSONS FROM THE AFRICAN EXPERIENCE
Presented by the ISPOR Egypt, Ghana, Nigeria and South Africa Regional Chapters

PROBLEMS, PITFALLS, AND PRAGMATICS OF PHARMACOECONOMICS: LESSONS FROM THE EGYPTIAN EXPERIENCE
Mohammed Hassan Solayman, MSc, Assistant Lecturer, Faculty of Pharmacy, Clinical Pharmacy Department, Ain Shams University, Cairo, Egypt

PROBLEMS, PITFALLS AND PRAGMATICS OF PHARMACOECONOMICS: LESSONS FROM THE AFRICAN EXPERIENCE: GHANA’S PERSPECTIVE
Martha Gyansa-Lutterodt,
MA, MSc, Director of Pharmaceutical Services and Chief Pharmacist, Ghana Ministry of Health, Accra, Ghana

PHARMACOECONOMICS IN NIGERIA: FROM FAITH TO EVIDENCE
Anthony Waka Udezi, MPharm, Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, University of Benin, Benin City, Nigeria

Dichotomy In Health Funding and Outcomes: The South African Experience
Jacques Snyman, MBChB, MPharmMed, MD, President, ISPOR South Africa Regional Chapter and Director, Product Development, Agility Global Health Solutions, Pretoria, South Africa

 
EDUCATIONAL SYMPOSIA
DEFENDING AGAINST THE DOUBLE DIP: PRACTICAL SOLUTIONS AND STRATEGIES FOR DEVELOPING PRODUCTS FOR COMMERCIAL SUCCESS THROUGH IMPROVED ACCESS BY UTILIZING HEALTH OUTCOMES DATA
(Sponsored by Parexel)

Designing Observational Research Programs to Demonstrate Product Value
Neal Mantick, BSPharm, MS, Senior Director & Global Head Observational Research, PAREXEL International, Waltham, MA, USA

The New Focus on Comparative Effectiveness Research
Grant P. Bagley, MD, JD, Senior Advisor, HillCo Health, Austin, TX, USA

Practical Solutions for Using Outcomes Data to Demonstrate the Value Proposition to Payers
Leeanne Larson, MHA, Vice President, Evidence Development, PAREXEL International, Waltham, MA, USA

Maximizing Oncology Access: Trends & Evolving Evidence Requirements
(Sponsored by Xcenda)
Thomas Bramley, RPh, PhD, Vice President, Global Value Strategies, Xcenda, Salt Lake City, UT, USA; Kara Suter, MS, Director, Health Policy, Xcenda, Washington, DC, USA; Peter Neumann, ScD, Professor of Medicine, Tufts University School of Medicine, Boston, MA, USA; Trent McLaughlin, PhD, Senior Director, Global HEOR Oncology & Cardiometabolic Disease, Abbott, Abbott Park, IL,USA

PHARMACOECONOMIC MODELING: THE ROAD TO PRIMETIME
(Sponsored by Archimedes)

PHARMACOECONOMIC MODELING: THE ROAD TO PRIMETIME
Névine Zariffa, MMath, Global Head Statistics and Programming, R&D, AstraZeneca, Wilmington, DE, USA

THE POLICYMAKER'S TOOLBOX
Janet Brock, Director, Division of Operations & Information Management, Coverage and Analysis Group, Office of Clinical Standards and Quality, CMS, Baltimore, MD, USA

FDA CDER' Benefit Risk Assessment Framework Lessons learned on the road to primetime
Sara Eggers, PhD, Economist, Office of Planning and Informatics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA

"Sea Change" or "C" Change? How Significant are the Differences Between CER& CEA and Why Does it Matter to Pharma?
(Sponsored by OptumInsight)
David Thompson, PhD, Executive Vice President & Senior Scientist, Health Economics & Outcomes Research, OptumInsight, Medford, MA, USA

Individual Treatment Effects From Research to Action
(Sponsored by the National Pharmaceutical Council)
Robert W. Dubois, MD, PhD, Chief Science Officer, National Pharmaceutical Council, Washington, DC, USA; Michael S. Lauer, MD, FACC, FAHA, Director, Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute, National Institutes of Health and Member, Patient-Centered
Outcomes Research Institute Methodology Committee, Bethesda, MD, USA;
Robert S. Epstein, MD, MS, Former Chief Medical Officer and President, Medco Research Institute, Medco Health Solutions, Inc., Franklin Lakes, NJ, USA


 


17th Annual International Meeting Main Page